e-learning
resources
Glasgow 2004
Wednesday 08.09.2004
Bronchiectasis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Absorption of nebulised gentamicin in patients with bronchiectasis
A. C. Boyter, J. P. Fuld, D. G. Watson, R. D. Stevenson (Glasgow, United Kingdom)
Source:
Annual Congress 2004 - Bronchiectasis
Session:
Bronchiectasis
Session type:
Oral Presentation
Number:
4336
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. C. Boyter, J. P. Fuld, D. G. Watson, R. D. Stevenson (Glasgow, United Kingdom). Absorption of nebulised gentamicin in patients with bronchiectasis. Eur Respir J 2004; 24: Suppl. 48, 4336
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Distribution of nebulised gentamicin in patients with bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004
Bronchospasm secondary to nebulised antibiotics in bronchiectasis
Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies
Year: 2017
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005
Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Pharmacokinetics of instilled
versus
nebulized tobramycin or Imipenem in mechanically ventilated ICU patients
Source: Eur Respir J 2002; 20: Suppl. 38, 16s
Year: 2002
Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic
pseudomonas aeruginosa
lung infection
Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Year: 2009
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Source: Eur Respir J 2002; 20: 658-664
Year: 2002
Nebulized saline treatment in patients with concomitant asthma and bronchiectasis
Source: Virtual Congress 2021 – Bronchiectasis and pleural infection
Year: 2021
Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016
The effect of nebulised colistimethate sodium on non-CF bronchiectasis with
pseudomonas aeruginosa
(preliminary report)
Source: Eur Respir J 2007; 30: Suppl. 51, 439s
Year: 2007
In-vitro comparison of tobramycin nebulised using two different nebuliser systems
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010
Efficacy and safety of TOBI Podhaler in
Pseudomonas aeruginosa-
infected bronchiectasis patients: iBEST study
Source: Eur Respir J, 57 (1) 2001451; 10.1183/13993003.01451-2020
Year: 2021
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011
The effect of tobramycin nebulised solution in COPD patients with Pseudomonas aeruginosa in sputum (preliminary report)
Source: Eur Respir J 2004; 24: Suppl. 48, 409s
Year: 2004
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020
Oral antibiotics vs placebo for exacerbations of paediatric bronchiectasis
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept